Loading
CD86 is one of the two B7 molecules on antigen-presenting cells that either wake a T cell up (through CD28) or calm it down (through CTLA-4). Ipilimumab works by stopping CTLA-4 from hogging CD86 and CD80. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Shares the CD28/CTLA-4 ligand role with CD80; no drug in the corpus binds CD86 directly.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD86" OR ABSTRACT:"CD86" OR TITLE:"B7-2" OR ABSTRACT:"B7-2" OR TITLE:"B7.2" OR ABSTRACT:"B7.2" OR TITLE:"CD28LG2" OR ABSTRACT:"CD28LG2" OR TITLE:"CD86 molecule" OR ABSTRACT:"CD86 molecule") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD86 (B7-2), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd86.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd86.json. Licence CC BY-NC 4.0.